Cervos Medical products

The CER-BN-116 is a bone dowel harvesting device that has an 11 gauge cannula and is designed to be powered by a drill. This device allows the capture of living autogenous bone. The initial stylet is used to penetrate the cortical bone.  A second shorter stylet is then used to advance the cannula to capture the core sample.  The device can be directed at various angles to the initial trajectory to allow for multiple dowels to be taken.  This device is often used in conjunction with the Cervos Bone Marrow Aspiration Devices and CellFuse Graft Material.  The device can used in conjunction with the CER-SUB-83N 8 gauge sub chondral access needle.  The access needle creates a working channel into the bone.

The CER-BN-84 is a bone dowel harvesting device that has an 8 gauge cannula and is designed to be powered by a drill.  This device allows the capture of living autogenous bone.  The initial stylet is used to penetrate the cortical bone.  A second shorter stylet is then used to advance the cannula to capture the core sample. The device can be directed at various angles to the initial trajectory to allow for multiple dowels to be taken.  This device is often used in conjunction with the Cervos Bone Marrow Aspiration Devices and CellFuse Graft Material.  Combining marrow aspirate with autogenous bone and a graft extender allows clinicians to fill boney defects using the patient’s own cells as the engine for bone healing. The combination of all three provide cells, signals and a scaffold; the building blocks for repairing bone.

CF-G5 A volume of 5cc of granules based on the patented highly cross-linked carbohydrate graft that has been cleared through the FDA 510(k) process (K170165).  The fetus develops tissues using a carbohydrate structure through glycosylation. This process continues in adulthood where leukocytes use the L-selectin on their surface to attach to damaged blood vessels which are coated with carbohydrate molecules.  

CF-G10 A volume of 10cc of granules based on the patented highly cross-linked carbohydrate graft that has been cleared through the FDA 510(k) process (K170165).  The fetus develops tissues using a carbohydrate structure through glycosylation. This process continues in adulthood where leukocytes use the L-selectin on their surface to attach to damaged blood vessels which are coated with carbohydrate molecules.